Adlai Nortye is a global clinical-stage biopharmaceutical company with several innovative late-stage immuno-oncology medicines in its pipeline. Our focus is to provide new options designed to transform historically hard-to-treat cancers into manageable conditions in the near-term -- so that patients are able to live longer and better -- while at the same time pursuing science that can lead to a cure. As a rapidly growing multinational company, we are working across borders and partnering around the world to change how cancer is treated.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):